US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.950
- +0.090+4.84%
Trading Aug 29 15:21 ET
36.09MMarket Cap-1839P/E (TTM)
1.980High1.810Low441.16KVolume1.900Open1.860Pre Close839.67KTurnover3.54%Turnover RatioLossP/E (Static)18.51MShares1.98052wk High3.62P/B24.34MFloat Cap0.42052wk Low--Dividend TTM12.48MShs Float184.000Historical High--Div YieldTTM9.13%Amplitude0.420Historical Low1.903Avg Price1Lot Size
Chemomab Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | -54.02%3.77M | -55.27%4.05M | -10.77%25.46M | 31.04%8.2M | 70.09%9.05M | 130.72%28.53M | 72.01%8.64M | 187.69%8.32M | 127.17%6.25M | 213.13%5.32M |
| Selling and administrative expenses | -73.54%840K | -56.71%936K | -38.75%7.08M | -4.94%3.18M | -16.04%2.16M | 91.55%11.56M | 4.01%2.75M | 106.13%2.89M | 130.98%3.34M | 375.09%2.58M |
| -General and administrative expense | -73.54%840K | -56.71%936K | -38.75%7.08M | -4.94%3.18M | -16.04%2.16M | 91.55%11.56M | 4.01%2.75M | 106.13%2.89M | 130.98%3.34M | 375.09%2.58M |
| Research and development costs | -41.67%2.93M | -54.81%3.11M | 8.27%18.38M | 72.27%5.02M | 150.89%6.89M | 168.03%16.98M | 147.38%5.9M | 264.69%5.42M | 122.95%2.91M | 137.25%2.75M |
| Operating profit | 54.02%-3.77M | 55.27%-4.05M | 10.77%-25.46M | -31.04%-8.2M | -70.09%-9.05M | -130.72%-28.53M | -72.01%-8.64M | -187.69%-8.32M | -127.17%-6.25M | -213.13%-5.32M |
| Net non-operating interest income expense | -47.10%137K | -43.22%180K | 250.71%1.24M | 153.96%259K | 46.76%317K | 418.02%353K | 3,266.67%380K | 407.79%237K | -2,723.53%-480K | 4,420.00%216K |
| Total other finance cost | 47.10%-137K | 43.22%-180K | -250.71%-1.24M | -153.96%-259K | -46.76%-317K | -418.02%-353K | -3,266.67%-380K | -407.79%-237K | 2,723.53%480K | -4,420.00%-216K |
| Other net income (expense) | ||||||||||
| Income before tax | 54.25%-3.63M | 55.70%-3.87M | 14.05%-24.22M | -17.85%-7.94M | -71.08%-8.73M | -125.84%-28.18M | -64.06%-8.26M | -172.24%-8.08M | -143.10%-6.73M | -199.53%-5.1M |
| Income tax | 0 | 0 | 0 | 106.25%34K | 21K | -534K | 10K | 0 | -544K | 0 |
| Net income | 54.44%-3.63M | 55.81%-3.87M | 12.39%-24.22M | -28.76%-7.97M | -71.49%-8.75M | -121.56%-27.65M | -64.26%-8.27M | -172.24%-8.08M | -123.47%-6.19M | -199.53%-5.1M |
| Net income continuous Operations | 54.44%-3.63M | 55.81%-3.87M | 12.39%-24.22M | -28.76%-7.97M | -71.49%-8.75M | -121.56%-27.65M | -64.26%-8.27M | -172.24%-8.08M | -123.47%-6.19M | -199.53%-5.1M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 54.44%-3.63M | 55.81%-3.87M | 12.39%-24.22M | -28.76%-7.97M | -71.49%-8.75M | -121.56%-27.65M | -64.26%-8.27M | -172.24%-8.08M | -123.47%-6.19M | -199.53%-5.1M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 54.44%-3.63M | 55.81%-3.87M | 12.39%-24.22M | -28.76%-7.97M | -71.49%-8.75M | -121.56%-27.65M | -64.26%-8.27M | -172.24%-8.08M | -123.47%-6.19M | -199.53%-5.1M |
| Basic earnings per share | 63.89%-0.26 | 65.00%-0.28 | 14.88%-2.06 | -33.33%-0.72 | -81.82%-0.8 | -101.67%-2.42 | -63.64%-0.72 | -169.23%-0.7 | -107.69%-0.54 | -100.00%-0.44 |
| Diluted earnings per share | 63.89%-0.26 | 65.00%-0.28 | 14.88%-2.06 | -33.33%-0.72 | -81.82%-0.8 | -101.67%-2.42 | -63.64%-0.72 | -169.23%-0.7 | -107.69%-0.54 | -100.00%-0.44 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
